NCT02125357View on ClinicalTrials.gov

Sequencing Abiraterone and Enzalutamide in mCRPC

PHASE2CompletedINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

February 4, 2020

Study Completion Date

February 4, 2020

Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
DRUG

Abiraterone acetate

Abiraterone acetate 1000mg PO OD with prednisone 5mg PO BID or 10mg OD as per standard of care.

DRUG

Enzalutamide

160mg PO OD as per standard of care.

Trial Locations (7)

V2S 0C2

BC Cancer Agency - Abbotsford, Abbotsford

V1Y 5L3

BC Cancer Agency - Southern Interior, Kelowna

V2N 7E9

BC Cancer Agency - Centre for the North, Prince George

V3V 1Z2

BC Cancer Agency - Fraser Valley, Surrey

V5Z 1M9

Vancouver Prostate Centre, Vancouver

V5Z 4E6

BC Cancer Agency - Vancouver Centre, Vancouver

V8R 6V5

BC Cancer Agency - Vancouver Island, Victoria

All Listed Sponsors
lead

British Columbia Cancer Agency

OTHER

NCT02125357 - Sequencing Abiraterone and Enzalutamide in mCRPC | Biotech Hunter | Biotech Hunter